Want to join the conversation?
$VRTX said that the FDA has rejected its supplemental New Drug Application for the use of KALYDECO (ivacaftor) in people with cystic fibrosis ages two and older with one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator gene. $VRTX plans to meet with the FDA to determine an appropriate path forward.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.